Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for NextCure, Inc. (NXTC : NSDQ)

• Company Description    NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company's product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland. Number of Employees: 43

• Price / Volume Information    Yesterday's Closing Price: $11.97 Daily Weekly Monthly 20 Day Moving Average: 84,600 shares Shares Outstanding: 2.68 (millions) Market Capitalization: $32.03 (millions) Beta: 1.34 52 Week High: $19.20 52 Week Low: $2.69 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 110.37% 104.89% 12 Week 131.98% 113.61% Year To Date 29.33% 10.39%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9000 VIRGINIA MANOR ROAD SUITE 200 - BELTSVILLE,MD 20705 USA ph: 240-399-4900 fax: - ir@nextcure.com http://www.nextcure.com

• General Corporate Information    Officers Michael Richman - President and Chief Executive Officer David Kabakoff - Chairman Steven P. Cobourn - Chief Financial Officer Anne Borgman - Director Ellen G. Feigal - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 65343E207 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 2.68 Most Recent Split Date: 7.00 (0.08:1) Beta: 1.34 Market Capitalization: $32.03 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-4.14 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-15.59 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.01 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -70.99% vs. Previous Quarter: -141.14% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - -106.62 03/31/25 - -70.16 ROA 09/30/25 - - 06/30/25 - -85.20 03/31/25 - -58.10 Current Ratio 09/30/25 - - 06/30/25 - 3.71 03/31/25 - 10.26 Quick Ratio 09/30/25 - - 06/30/25 - 3.71 03/31/25 - 10.26 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - 11.82 03/31/25 - 23.91 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©